-
In Case You Missed It…
Quest Media is an innovative adaptive lifestyle platform from MDA. With the power of this […]
-
Exon-skipping therapy shows promise for DMD44
Delpacibart zotadirsen (del-zota), an investigational exon-skipping therapy from Avidity Biosciences, is demonstrating the potential to […]
-
Exon-skipping therapy shows promise for DMD44
Delpacibart zotadirsen (del-zota), an investigational exon-skipping therapy from Avidity Biosciences, is demonstrating the potential to […]
-
The how and why of living with limb-girdle muscular dystrophy
“He who has a why to live can bear almost any how.” — Friedrich Nietzsche I […]
-
Employer Matching Programs Double the Impact
Anybody who has made a monetary donation to support MDA’s mission knows well that their […]
-
Agamree : un premier traitement approuvé au Canada pour la DMD
Le 25 septembre 2025, Santé Canada a franchi une étape historique en approuvant AGAMREE® (vamorolone) […]
-
Just another Monday: Watch movie, do laundry, throw out my back
Mondays are one of my favorite days of the week as a busy mom to […]
-
CureDuchenne Cares Webinar: Optimizing Cardiac Outcomes in Duchenne
CureDuchenne and Andreas S. Barth, MD, PhD, FAHA, for a community webinar about Optimizing Cardiac […]
-
Motor function linked to weight, height changes in boys with DMD
For boys who start corticosteroids to treat Duchenne muscular dystrophy (DMD), being taller is linked […]
-
MDA Ambassador Guest Blog: Entrepreneurship, Advocacy, and Innovation: Building a More Accessible Future from the Inside Out
Owen Kent is the co-founder and Chief Marketing Officer of Assistive Technology Development (ATDev), a […]
